Evidence map›Paper›PMID 36839825›Full record

ReviewPharmaceutics2023

Recent Advances in Cancer Immunotherapy Delivery Modalities.

Palaniyandi Muthukutty, Hyun Young Woo, Murali Ragothaman, So Young Yoo

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Gut Microbiota-Based Immunotherapy: EngineeredMedicina (Kaunas, Lithuania) · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Palaniyandi MuthukuttyBIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0003-1173-335X
Hyun Young WooDepartment of Internal Medicine and Medical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
Murali RagothamanBIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.
So Young YooBIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0001-8875-9289
Pusan National University · KRPusan National University Hospital · KR

Funding

Biomedical Research Institute Grant, Pusan National University Hospital. 20220033
6 · The paper itself

Abstract

Immunotherapy is crucial in fighting cancer and achieving successful remission. Many novel strategies have recently developed, but there are still some obstacles to overcome before we can effectively attack the cancer cells and decimate the cancer environment by inducing a cascade of immune responses. To successfully demonstrate antitumor activity, immune cells must be delivered to cancer cells and exposed to the immune system. Such cutting-edge technology necessitates meticulously designed delivery methods with no loss or superior homing onto cancer environments, as well as high therapeutic efficacy and fewer adverse events. In this paper, we discuss recent advances in cancer immunotherapy delivery techniques, as well as their future prospects.

Indexed as

cancer immunotherapyCAR-T cellsdrug deliverynanoparticles

Identifiers

PMID36839825
PMCPMC9967630
OpenAlexW4319158556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.